Hudson Bay Capital Management
SLNO

Hudson Bay Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Hudson Bay Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,600
Closed -$4.89M – 1574
2025
Q4 		$4.89M Sell
105,600
-154,400
-59% -$8.47M 0.02% 506
2025
Q3 		$17.6M Buy
260,000
+10,000
+4% +$741K 0.06% 251
2025
Q2 		$20.9M Buy
250,000
+225,000
+900% +$16.8M 0.07% 208
2025
Q1 		$1.79M Buy
+25,000
New +$1.22M 0.01% 840

Hudson Bay Capital Management's SLNO Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 203,291 shares — an estimated $6.81M sold.

Hudson Bay Capital Management first reported a position in SLNO in Q4 2014 and held it in 7 quarters. The position peaked at $6.81M in Q1 2026. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 203,291 Soleno Therapeutics shares in Q2 2026, an estimated $6.81M.
  • Hudson Bay Capital Management first reported a position in Soleno Therapeutics in Q4 2014 and held it in 7 quarters.
  • Hudson Bay Capital Management's Soleno Therapeutics position peaked at $6.81M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.